+44 (0)20 3910 4640 hello@symmetron.net
  • Twitter
  • Twitter
Symmetron
  • Services
  • Success stories
  • Therapeutic areas
  • Insights
  • The team
  • Careers
  • Contact
Select Page

Unmet medical need and market access: enabler or barrier to innovation?

by Kirsten Chalmers | Aug 17, 2022 | Health technology assessment, Healthcare, Market access, NICE

Insights Unmet medical need and market access: enabler or barrier to innovation? Designed to help healthcare stakeholders identify more urgent health needs, the concept of “unmet medical need” is being increasingly applied formally and informally to set priorities...

Market access for immuno-oncology (I-O) therapies in the UK

by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology

Insights Market access for immuno-oncology (I-O) therapies in the UK The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing...
  • January 2023
  • December 2022
  • August 2022
  • May 2022
  • November 2021
  • October 2021
  • August 2021
  • July 2021
  • Budget impact
  • Clinical trial
  • Cost-effectiveness analysis
  • Decision analytic
  • Discrete event simulation
  • Evidence generation
  • Evidence synthesis
  • glossary
  • Health economic modelling
  • Health outcomes
  • Health technology assessment
  • Healthcare
  • Market access
  • Medical affairs
  • NICE
  • Oncology
  • Services
  • Success stories
  • Therapeutic areas
  • Insights
  • The team
  • Careers
  • Contact
  • Privacy Policy
  • LinkedIn
  • Twitter
© 2021 Symmetron Limited